Liquidia Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Liquidia (LQDA) received FDA Fast Track designation for YUTREPIA, a treatment for Raynaud's phenomenon in systemic sclerosis. The company plans a Phase 2a trial in 2026. LQDA stock closed at $69.68, up 4.14%, and is up 1.18% in pre-market trading.
Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.
Adair Jason (Chief Business Officer) sold 73,631 shares of Liquidia Corp (LQDA) at $69.09 ($5.09M total) across 2 trades on 2026-08-21 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning LQDA (Liquidia Corp). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent LQDA coverage spans earnings, insider activity and regulation.
In the last 30 days, LQDA insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($15.2M). The most active reporter was Rielly-Gauvin Katherine with 2 filings. 71% of those filings were made under pre-arranged Rule 10b5-1 plans.
Fast Track status could accelerate development and boost market perception.
First disclosure of H1 sales and guidance downgrade suggests near‑term earnings pressure but confirms strong product traction.
The insider sale may signal confidence concerns, potentially pressuring the stock short term.
The insider sale may signal reduced confidence, potentially exerting slight downward pressure on LQDA.
Insider sale may signal reduced confidence or need for liquidity, potentially pressuring the stock short-term.
alphai scores every news story that mentions LQDA with an AI model for sentiment and relevance, and aggregates insider trades from Liquidia Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Liquidia (LQDA) received FDA Fast Track designation for YUTREPIA, a treatment for Raynaud's phenomenon in systemic sclerosis. The company plans a Phase 2a trial in 2026. LQDA stock closed at $69.68, up 4.14%, and is up 1.18% in pre-market trading.
2 min readLiquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.
2 min readAdair Jason (Chief Business Officer) sold 73,631 shares of Liquidia Corp (LQDA) at $69.09 ($5.09M total) across 2 trades on 2026-08-21 under a Rule 10b5-1 trading plan.
1 min readRielly-Gauvin Katherine sold 55,182 shares of Liquidia Corp (LQDA) at an average of $74.07 ($72.23–$74.99, $4.09M total) across 2 trades over 2026-08-19 to 2026-08-20 under a Rule 10b5-1 trading plan.
1 min readSaggar Rajeev (Chief Medical Officer) sold 79,534 shares of Liquidia Corp (LQDA) at an average of $75.09 ($74.06–$76.84, $5.97M total) across 2 trades over 2026-08-17 to 2026-08-19.
1 min readLiquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.
3 min readLiquidia (LQDA) reported Q2 2026 results with revenue of $171.68 million versus $8.84 million a year earlier, and it swung from a net loss to net income of $74.72 million. For H1 2026, net income rose to $127.58 million from a $79.95 million loss. The article discusses how this profitability shift affects its YUTREPIA and L606 outlook.
7 min readLiquidia’s Q2 2026 earnings call said YUTREPIA net sales rose 31% sequentially to $170.4 million, with four quarters of improving profitability. Management attributed adoption to a tolerability-first approach and said YUTREPIA has about 30% share of the inhaled market. It reiterated confidence in >$1 billion net revenue by 2027 and plans higher H2 2026 R&D for trials.
6 min readLiquidia (LQDA) fell sharply after reporting Q2 results. The company said revenue rose to about $171.7M versus $8.8M a year earlier, driven mainly by higher sales volume of its commercial drug Yutrepia. Liquidia reported GAAP net income of $74.7M, or $0.74 per share, slightly below the $0.76 consensus. Shares were down about 20% week to date.
3 min readLiquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.
7 min read
